TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.

ABSTRACT:

Background/purpose

TrkA overexpression occurs in over 20% of breast cancers, including triple-negative breast cancers (TNBC), and has recently been recognized as a potential driver of carcinogenesis. Recent clinical trials of pan-Trk inhibitors have demonstrated targeted activity against tumors harboring NTRK fusions, a relatively rare alteration across human cancers. Despite this success, current clinical trials have not investigated TrkA overexpression as an additional therapeutic target for pan-Trk inhibitors. Here, we evaluate the cancerous phenotypes of TrkA overexpression relative to NTRK1 fusions in human cells and assess response to pharmacologic Trk inhibition.

Experimental design/methods

To evaluate the clinical utility of TrkA overexpression, a panel of TrkA overe

SUBMITTER: Kyker-Snowman K 

PROVIDER: S-EPMC7337566 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature